RE:The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't" Raghav Mittal, assistant director at research firm Acuity Knowledge Partners, said in an email that acquisitions of biotech companies working on oncology or immunology treatments could be worth $5 billion to $25 billion a pop."
Well it appears that biotech analysts now view Big Pharm's M&A "sweet spot" as expanding to US$25 Billion.
Consequently ONCY'S acquisition value at US$10 Billion to US$15 Billion has become a very real proposition.